SGLT2 Inhibitors Enhance Kidney Outcomes Across HF, CKD, and Diabetes
The following is a summary of “Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses,” published in ...
